

**Thursday 22<sup>nd</sup> February 2018**  
**IACR Scientific Sessions**

09.00 - 09.10: **Welcome Address and Opening of Conference**  
**Prof Amanda McCann (IACR President)**

**PLENARY SESSION 1: REPORTS FROM CLINICAL TRIALS IN LOW SURVIVAL CANCERS**

*This Session has been kindly sponsored by Breakthrough Cancer Research*

**Chairpersons: Dr Patrick Kiely and Dr James Brown**

09.10-09.15 **Eoghan O’Sullivan, Breakthrough Cancer Research**

09.15-09.45 **PRECISION ONCOLOGY FOR PANCREATICOBILIARY CANCERS – SUCCESSES, CHALLENGES AND FUTURE DIRECTIONS**  
*Professor Maeve Lowery, Professor of Translational Cancer Medicine, Trinity College Dublin*

09.45-10.15 **CLINICAL CHALLENGE IN IMPROVING TREATMENT RESPONSE RATES FOR OESOPHAGEAL CANCER PATIENTS: IMPORTANCE OF TRANSLATIONAL RESEARCH**  
*Professor Jacintha O’Sullivan, Professor in Translational Oncology, Trinity Translational Medicine Institute (TTMI), St. James’s Hospital, Dublin*

10.15-10.45 **IMMUNOTHERAPY FOR LUNG CANCER, REAL HOPE OR EXPENSIVE HYPE?**  
*Dr Frances Shepherd, University Health Network, Toronto, Canada*

10.30-10.45 **GOLD SPONSOR PRESENTATION**  
**Detangling the complexities of Immuno Oncology**  
**Dr. Jim White, Ph.D. Manager, EMEA Field Application Scientists nanoString Technologies Inc**

10.45-11.15 **TEA/COFFEE/POSTERS & MEET THE SPONSORS**

**PLENARY SESSION 2: NANOMEDICINE IN CANCER TREATMENT**

**Chairpersons: Dr Olga Piskareva and Dr Brona Murphy**

11.15-11.45 **SMART AND THERANOSTICS NANOMATERIALS FOR STIMULI-RESPONSIVE THERAPIES AGAINST CANCER**  
*Prof. Valentina Cauda, Department of Applied Science and Technology (DISAT), Politecnico di Torino, Italy*

11.45-12.15 **POLYMERIC MICELLES AND NANOGELS FOR MULTI-DRUG DELIVERY IN OVARIAN CANCER THERAPY**  
*Dr Hyunah Cho, Assistant Professor, School of Pharmacy and Health Sciences, Fairleigh Dickinson University, New Jersey, USA*

12.15-12.45 **CONTROLLING THE RELEASE OF CHEMOTHERAPEUTICS WITH NANOPARTICLE-HYDROGEL COMPOSITES**  
*Professor Eduardo Ruiz-Hernandez, School of Pharmacy, Trinity College Dublin*

12.45-13.00 **GOLD SPONSOR PRESENTATION**  
**Live Cell In-Vitro Assays for Oncology Discovery Biology and Therapeutic Development, Using Real-Time Kinetic Data from xCELLigence Impedance Biosensors**  
**William Deacon MSc, ACEA, xCELLigence Sales Manager**

13.00-14.15 **LUNCH**

- 14.15-15.08 **ORAL POSTER PRESENTATIONS (Prof. John Fitzpatrick Medal)**  
**Chaired by Prof. Amanda McCann and Dr Antoinette Perry**  
 (8 x 6 minute presentations, selected from Abstract Submissions)
- 14.15-14.26 **PROTEIN AND CHEMOTHERAPY PROFILING OF EXTRACELLULAR VESICLES HARVESTED FROM THERAPEUTIC INDUCED SENESCENCE TRIPLE NEGATIVE BREAST CANCER CELLS.**  
**Emma L Kavanagh**<sup>1</sup>, S Lindsay <sup>1</sup>, M Halasz <sup>2,3</sup>, LC Gubbins <sup>1</sup>, K Weiner-Gorzel<sup>1</sup>, MHZ Guang <sup>1</sup>, A McGoldrick <sup>1</sup>, E Collins <sup>1</sup>, M Henry <sup>4</sup>, A Blanco-Fernandez <sup>1</sup>, P O' Gorman <sup>5</sup>, P Fitzpatrick <sup>6</sup>, MJ Higgins <sup>7</sup>, P Dowling <sup>8</sup>, A McCann<sup>1,3</sup>  
<sup>1</sup>UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin (UCD), Dublin, <sup>2</sup>Systems Biology Ireland (SBI), University College Dublin (UCD), Dublin, <sup>3</sup>UCD School of Medicine, College of Health and Agricultural Science, University College Dublin (UCD), Dublin, <sup>4</sup>National Institute for Cellular Biotechnology, Dublin City University, Dublin, <sup>5</sup>Haematology Department, Mater Misericordiae University Hospital, Dublin, <sup>6</sup>UCD School of Public Health, University College Dublin (UCD), Dublin, <sup>7</sup>Oncology Department, Mater Misericordiae University Hospital, Dublin, <sup>8</sup>Biology Department, National University of Ireland Maynooth, Kildare, Ireland
- 14.26-14.32 **3D TISSUE-ENGINEERED CELL MODEL OF NEUROBLASTOMA FOR EVALUATING CYTOTOXIC AND MIRNA-TARGETED THERAPEUTICS**  
**Olga Piskareva**<sup>1,2</sup>, C Curtin<sup>3,4</sup>, J Nolan<sup>1,2</sup>, R Conlon<sup>1</sup>, C Gallagher<sup>1</sup>, L Deneweth<sup>1</sup>, BL Cavanagh<sup>5</sup>, H Harvey<sup>1</sup>, S Miller-Delaney<sup>1</sup>, I Bray<sup>1</sup>, FJ O'Brien<sup>3,4</sup>, RL Stallings<sup>1,2</sup>  
<sup>1</sup>Molecular & Cellular Therapeutics, College of Surgeons in Ireland, Dublin  
<sup>2</sup>National Children's Research Centre, Our Lady's Children's Hospital, Dublin  
<sup>3</sup>Tissue Engineering Research Group, College of Surgeons in Ireland, Dublin  
<sup>4</sup>Advanced Materials and Bioengineering Research Centre, RCSI & TCD, Dublin  
<sup>5</sup>Cellular and Molecular Imaging Core, College of Surgeons in Ireland, Dublin
- 14.32-14.38 **RNA SEQUENCING IDENTIFIES BRD3 AS A NOVEL THERAPEUTIC TARGET IN INVASIVE LOBULAR CARCINOMA BREAST CANCER**  
**Kathryn Haley**, L Walsh<sup>1,8</sup>, F Tarrant<sup>2</sup>, B Moran<sup>2</sup>, S Das<sup>1</sup>, D Vareslija<sup>3</sup>, C Dowling<sup>8</sup>, P Schouten<sup>4</sup>, SF Chin<sup>5</sup>, R Bernards<sup>6</sup>, C Caldas<sup>7</sup>, L Young<sup>3</sup>, WM Gallagher<sup>2</sup>, T Ní Chonghaile<sup>\*8</sup>, DP O'Connor<sup>\*1</sup>  
<sup>1</sup>Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin  
<sup>2</sup>School of Biomolecular and Biomedical Science, University College Dublin, Dublin  
<sup>3</sup>Surgery, Royal College of Surgeons in Ireland, Dublin  
<sup>4</sup>Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam  
<sup>5</sup>Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge  
<sup>6</sup>Cancer Genomics Netherlands, The Netherlands Cancer Institute, Amsterdam  
<sup>7</sup>Oncology, University of Cambridge, Cambridge  
<sup>8</sup>Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin
- 14.38-14.44 **NEW ROLE OF MYCN IN THE MITOCHONDRIA: ANTI-CANCER EFFECTS OF DIPHENYLENEIODONIUM CHLORIDE (DPI) IN MYCN-AMPLIFIED NEUROBLASTOMA**  
**Simone Marcone**<sup>1</sup>, K Iljin<sup>2</sup>, E Dempsey<sup>3</sup>, D Fey<sup>1</sup>, DJ Duffy<sup>1</sup>, F Westermann<sup>4</sup>, W Kolch<sup>1</sup>, M Halasz<sup>1</sup>  
<sup>1</sup>Systems Biology Ireland, University College Dublin, Dublin  
<sup>2</sup>VTT Technical Research Centre of Finland, Oulu, Finland  
<sup>3</sup>School of Biology and Environmental Science, University College Dublin, Dublin  
<sup>4</sup>DKFZ German Cancer Research Centre, Heidelberg, Germany

- 14.44-14.50 **TIME FOR A NEW TAXOL? PROMISING ANTI-CANCEROUS PROPERTIES OF A NOVEL NATURAL COMPOUND CRASSIN IN TRIPLE-NEGATIVE BREAST CANCER CELLS**  
**Cathy E Richards**<sup>1</sup>, SH Vellanki<sup>1</sup>, YE Smith<sup>1</sup>, AM Hopkins<sup>1,2</sup>  
<sup>1</sup>Department of Surgery, Royal College of Surgeons in Ireland, Dublin  
<sup>2</sup>Royal College of Surgeons in Ireland, RCSI Smurfit Building, Beaumont Hospital, Dublin 9
- 14.50-14.56 **THE UNIDIRECTIONAL HYPOXIA-ACTIVATED PRODRUG OCT1002 INHIBITS GROWTH AND VASCULAR DEVELOPMENT IN CASTRATE-RESISTANT PROSTATE TUMOURS**  
**H Nesbitt**<sup>1</sup>, J Worthington<sup>2</sup>, RJ Errington<sup>3,4</sup>, LH Patterson<sup>5</sup>, PJ SMith<sup>5</sup>, SR McKeown<sup>1,5</sup>, DJ McKenna<sup>1</sup>  
<sup>1</sup>Biomedical Sciences Research Institute, University of Ulster, Coleraine, <sup>2</sup>Axis Bioservices Ltd, Coleraine, <sup>3</sup>School of Medicine, Cardiff University, Cardiff  
<sup>4</sup>BioStatus Ltd, Shepshed, Leicestershire, <sup>5</sup>OncoTherics Ltd, Shepshed, Leicestershire
- 14.56-15.02 **A COMPENDIUM OF CO-REGULATED PROTEIN COMPLEXES IN BREAST CANCER REVEALS COLLATERAL LOSS EVENTS**  
**Colm J Ryan**<sup>1,2</sup>, S Kennedy<sup>1</sup>, I Bajrami<sup>3</sup>, D Matallanas<sup>1</sup>, CJ Lord<sup>3</sup>  
<sup>1</sup>Systems Biology Ireland, University College Dublin, Dublin  
<sup>2</sup>School of Computer Science, University College Dublin, Dublin  
<sup>3</sup>The Breast Cancer Now Toby Robins Breast Cancer Research Centre, Institute of Cancer Research, London
- 15.02-15.08 **USING IN VITRO MODELS TO IDENTIFY NEWLY SYNTHESISED PROTEINS INVOLVED IN THE PROGRESSION OF TRIPLE NEGATIVE BREAST CANCER.**  
**Amira F Mahdi**<sup>1</sup>, B Malacrida<sup>1</sup>, K McGourty<sup>2</sup>, AJ Lowery<sup>3</sup>, PA Kiely<sup>1</sup>  
<sup>1</sup>Graduate Entry Medical School and Health Research Institute, University of Limerick, Limerick, <sup>2</sup>Department of Chemical Sciences, Bernal Institute, University of Limerick, Limerick, <sup>3</sup>Lambe Institute for Translational Research , NUI Galway , Galway
- 15.15- 15.45 **TEA/COFFEE/POSTERS & MEET THE SPONSORS**
- 15.45-16.45 **IRISH CANCER SOCIETY SCHOLAR AND FELLOW PRESENTATIONS**  
**Chairpersons: Dr Naomi Walsh and Dr Stephen Maher**  
 (The highest scoring abstracts from 2 x ICS funded PhD students and 2 x ICS funded Postdocs will be selected for presentation)
- 15.45-16.00 **SELECTIVE HDAC6 INHIBITION WITH ACY-1215 PROMOTED RESISTANCE TO PACLITAXEL IN EPITHELIAL OVARIAN CANCER**  
 K Weiner-Gorzel<sup>1</sup>, T Byrne<sup>2</sup>, A McGoldrick<sup>1</sup>, C Beggan<sup>3</sup>, N Faheem<sup>1</sup>, P Cunnea<sup>4</sup>, E Dempsey<sup>5</sup>, S O'Toole<sup>6</sup>, J O'Leary<sup>6</sup>, E Kay<sup>3</sup>, T Robson<sup>7</sup>, A McCann<sup>1</sup>, **Fiona Furlong**<sup>2</sup>  
<sup>1</sup>UCD School of Medicine and Medical Science (SMMS), University College Dublin  
<sup>2</sup>School of Pharmacy, Queens University Belfast, Belfast  
<sup>3</sup>Department of Pathology, Royal College of Surgeons, Dublin  
<sup>4</sup>Department of Cancer and Surgery, Imperial College London, London  
<sup>5</sup>UCD School of Biomolecular and Biomedical Science (SBBS), University College Dublin, <sup>6</sup>Departments of Histopathology, Obstetrics and Gynaecology, Trinity College Dublin, <sup>7</sup>Molecular and Cellular Therapeutics, Royal College of Surgeons, Dublin

- 16.00-16.15 **BRINGING APOPTO-CELL, A PROGNOSTIC MARKER OF APOPTOSIS SIGNALLING, CLOSER TO CLINICAL INTEGRATION**  
(Post-doc)  
**Manuela Salvucci**<sup>1</sup>, A Rahman<sup>2</sup>, A Resler<sup>1</sup>, G Mallya Udipi<sup>2</sup>, DA McNamara<sup>3</sup>, EW Kay<sup>1,4</sup>, P Laurent-Puig<sup>5</sup>, DB Longley<sup>6</sup>, M Lawler<sup>6</sup>, R Wilson<sup>6</sup>, M Salto-Tellez<sup>6</sup>, S Van Schaeuybroeck<sup>6</sup>, M Rafferty<sup>2</sup>, W Gallagher<sup>2</sup>, M Rehm<sup>1,7</sup>, JHM Prehn<sup>1</sup>  
<sup>1</sup>Centre for Systems Medicine, Department of Physiology & Medical Physics, Royal College of Surgeons in Ireland, Dublin, <sup>2</sup>OncoMark Ltd, Dublin, <sup>3</sup>Department of Surgery, Beaumont Hospital, Dublin, <sup>4</sup>Department of Pathology, Beaumont Hospital, Dublin, <sup>5</sup>Personalized Medicine, Pharmacogenomics, Therapeutic Optimization, Université Paris Descartes, Paris, France  
<sup>6</sup>Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast, <sup>7</sup>Institute of Cell Biology and Immunology, University of Stuttgart, Stuttgart, Germany
- 16.15-16.30 **TEMPORAL ANALYSIS IDENTIFIES NEUTROPHIL-LYMPHOCYTE RATIO VELOCITY PRE-RADIOTHERAPY as a potential prognostic indicator in localized prostate cancer**  
(PhD)  
**Sophia R Halliday**<sup>1</sup>, C,A Lyons<sup>1</sup>, S Jain<sup>1</sup>, J,M O'Sullivan<sup>1</sup>, D Mitchel<sup>2</sup>, L McCrink<sup>3</sup>, R,D Kennedy<sup>1,4</sup>, J,K Blayney<sup>1</sup>  
<sup>1</sup>Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast  
<sup>2</sup>Oncology, Belfast Health & Social Care Trust, Belfast, <sup>3</sup>Centre for Statistical Science & Operational Research, Queen's University Belfast, Belfast, <sup>4</sup>Almac Diagnostics, Almac, Belfast
- 16.30-16.45 **PROTEOSTATIC STRESS REVERTS THE LEUKAEMIA-SUPPORTING BONE MARROW MICROENVIRONMENT TO A LEUKAEMIA-REJECTING MICROENVIRONMENT**  
(PhD)  
**SPS Dhami**<sup>1</sup>, M Reidy<sup>1</sup>, M O'Dwyer<sup>1,2</sup>, E Szegezdi<sup>1</sup>  
<sup>1</sup>Apoptosis Research Centre, National University of Ireland, Galway  
<sup>2</sup>Department of Haematology, University Hospital Galway, Galway
- 17.00-17.30 **NEW FRONTIERS IN IRISH CANCER RESEARCH**  
**Dr Robert O'Connor, Irish Cancer Society**
- 17.30-18.30 **IRISH CANCER SOCIETY LECTURE**  
**MOLECULAR AND FUNCTIONAL DIVERSITY OF EXOSOMES AND OTHER EXTRACELLULAR VESICLES IN TUMOR-IMMUNE SYSTEM CROSS-TALK**  
**Professor Clotilde Théry, The Institut Curie, France**
- 18.45–21.30 **FORMAL POSTER SESSION**
- 18.45 -20.30 Buffet Dinner and Wine Reception
- 19.30--20.30 TRADE EXHIBITION/ /Presentation of odd Poster Numbers
- 20.30-21.30 TRADE EXHIBITION/ **Coffee and Dessert**/Presentation of even Poster Numbers

**Friday 23<sup>rd</sup> February 2018**  
**IACR Scientific Sessions**

- 09.00 -10.30: **PROFFERED PAPER SESSION (selected from Abstract Submissions)**  
**Chairpersons: Dr Paul Dowling and Dr Declan McKenna**  
6 x 15 minute presentations (12 mins + 3 mins Q&A)
- 09.00-09.15 **INSULIN-LIKE GROWTH FACTOR-1 SIGNALLING PROMOTES MITOCHONDRIAL PROTECTION IN CANCER CELLS**  
**Sarah Riis<sup>1</sup>, A Lyons<sup>1</sup>, M Coleman<sup>1</sup>, C Favre<sup>1</sup>, CH O'Flanagan<sup>2</sup>, AV Zhdanov<sup>3</sup>, DB Papkovsky<sup>3</sup>, SD Hursting<sup>2</sup>, R O'Connor<sup>1</sup>**  
<sup>1</sup>School of Biochemistry and Cell Biology, University College Cork, <sup>2</sup>Division of Nutritional Biochemistry, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, <sup>3</sup>Biophysics and Bioanalysis Laboratory, University College Cork, Cork
- 09.15-09.30 **JUNCTIONAL ADHESION MOLECULE-A (JAM-A) AS A NOVEL FUTURE DRUG TARGET IN DUCTAL CARCINOMA IN SITU (DCIS)**  
**Yvonne E Smith<sup>1</sup>, K Brennan<sup>1</sup>, L Hudson<sup>1</sup>, AO Leech<sup>1</sup>, SH Vellanki<sup>1</sup>, AM Hopkins<sup>1</sup>**  
<sup>1</sup>Department of Surgery, Royal College of Surgeons in Ireland, Beaumont Hospital, Beaumont, Dublin 9
- 09.30-09.45 **THE NOVEL DETECTION OF THE EGFR-T790M MUTATION IN EXHALED BREATH CONDENSATE**  
**Robert J Smyth<sup>1</sup>, S Toomey<sup>1</sup>, A Sartori<sup>2</sup>, E Hanrahan<sup>3</sup>, S Cuffe<sup>4</sup>, O Breathnach<sup>5</sup>, R Morgan<sup>6</sup>, BT Hennessy<sup>1</sup>**  
<sup>1</sup>Medical Oncology, RCSI, Dublin, <sup>2</sup> Agena Bioscience, Hamburg, <sup>3</sup>Medical Oncology, St Vincent's University Hospital, Dublin, <sup>4</sup>Medical Oncology, St James's Hospital, Dublin, <sup>5</sup>Medical Oncology, Beaumont Hospital, Dublin, <sup>6</sup>Respiratory Medicine, Beaumont Hospital, Dublin
- 09.45-10.00 **p53 ACTIVATION INDUCES A TARGETABLE DEPENDENCE ON FLIP<sub>L</sub>**  
**A McIntyre<sup>1</sup>, A Lees<sup>1</sup>, F Falcone<sup>1</sup>, C Holohan<sup>1</sup>, T Sessler<sup>1</sup>, G Gregg<sup>1</sup>, G Quinn<sup>1</sup>, J Crawford<sup>1</sup>, N Crawford<sup>1</sup>, J Fox<sup>1</sup>, J Majkut<sup>1</sup>, C Higgins<sup>1</sup>, L Egan<sup>2</sup>, A Ryan<sup>2</sup>, D McArt<sup>1</sup>, PD Dunne<sup>1</sup>, M Lawler<sup>1</sup>, PG Johnston<sup>1</sup>, DB Longley<sup>1</sup>, **Simon S McDade<sup>1</sup>**  
<sup>1</sup>CCRCB, Queen's University, Belfast, <sup>2</sup>, NUIG, Galway**
- 10.00-10.15 **THE TWO SIDES OF METFORMIN – A SUPPRESSOR OF TUMOUR CELL PROLIFERATION AND CANCER IMMUNOSURVEILLANCE**  
**Lydia Dyck<sup>1</sup>, X Michelet<sup>2,3</sup>, A Douglas<sup>1</sup>, RM Loftus<sup>1</sup>, H Prendeville<sup>1</sup>, KHG Mills<sup>1</sup>, L Lynch<sup>1,2,3</sup>**  
<sup>1</sup>School of Biochemistry and Immunology, Trinity College Dublin, Dublin  
<sup>2</sup>, Brigham and Women's Hospital, Boston  
<sup>3</sup>, Harvard Medical School, Boston
- 10.15-10.30 **MODULATION OF DRUG RESISTANCE IN HIGH-RISK NEUROBLASTOMA THROUGH EXOSOMAL MiRNA.**  
**John Christopher Nolan<sup>1,2</sup>, R Conlon<sup>1</sup>, T Frawley<sup>1</sup>, RL Stallings<sup>1,2</sup>, O Piskareva<sup>1,2</sup>**  
<sup>1</sup>Cancer Genetics Group, RCSI, Dublin  
<sup>2</sup>National Children's Research Centre, OLCHC, Dublin
- 10.30-11.00 **TEA/COFFEE/POSTERS/MEET THE SPONSORS**

**PLENARY SESSION 3: CELLULAR STRESS AND CANCER**

**Chairpersons: Dr Aileen Houston and Dr Graham Pidgeon**

- 11.00-11.30 **TARGETING THE IRE1 SIGNALLING AXIS IN BREAST CANCER**  
*Dr Susan Logue, Apoptosis Research Centre, NUI, Galway*
- 11.30-12.00 **COMPLEXITY OF IRE1 SIGNALING IN TUMOR DEVELOPMENT AND THERAPEUTIC OPPORTUNITIES**  
*Dr Eric Chevet, INSERM U1242, "Oncogenesis, Stress, Signaling", Université de Rennes, Rennes, France. Centre de Lutte Contre le Cancer Eugène Marquis, Rennes, France*
- 12.00-12.30 **DIRECTING CANCER THERAPY WITH MITOCHONDRIAL BH3 PROFILING**  
*Professor Tony Letai, Harvard Medical School, USA*
- 12.30-12.50 **IACR AGM – All Welcome**
- 12.30-13.45 **LUNCH**

**PLENARY SESSION 4: EMERGING TECHNIQUES IN BIOMARKER DISCOVERY, DRUG DEVELOPMENT AND PATIENT STRATIFICATION**

**Chairpersons: Dr Triona NiChonghaile and Dr Simon McDade**

- 13.45-14.15 **THE POWER OF 1: WHAT CAN WE LEARN FROM MOLECULAR CASE STUDIES?**  
*Dr Darran O'Connor, Clinical Pharmacology, RCSI, Dublin*
- 14.15-14.45 **PRECISION ONCOLOGY APPROACHES IN BREAST CANCER – CLINICAL EXPERIENCE AND ANIMAL MODELS**  
*Professor Paraic Kenny, Kabara Cancer Research Institute, Wisconsin, USA*
- 14.45-15.15 **PROGNOSTIC AND PREDICTIVE RADIOMICS AND PATHOMICS: IMPLICATIONS FOR PRECISION MEDICINE**  
*Dr Anant Madabhushi, Case Western Reserve University, Ohio, USA*
- 15.15-15.30 **GOLD SPONSOR PRESENTATION**  
**"How to manufacture your own T-cell immunotherapies"**  
**Lee Markwick Ph. D., Miltenyi Biotec Ltd**
- 15.30-15.45 **TEA/COFFEE/POSTERS/MEET THE SPONSORS**
- 15.45-16.45 **EACR YOUNG SCIENTIST AWARDS**  
**Chairpersons: Dr Ken Nally and Dr Marion Butler**  
**(2 x 25 mins + 5 mins Q&A)**
- 15.45-16.15 **MUTANT P53 AS A THERAPEUTIC TARGET FOR THE TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER: PRECLINICAL INVESTIGATION WITH THE ANTI-P53 DRUG, PK11007**  
**Naoise C Synnott<sup>1</sup>, MR Bauer<sup>2</sup>, SF Madden<sup>3</sup>, A Murray<sup>1</sup>, R Klinger<sup>4</sup>, D O'Connor<sup>5</sup>, WM Gallagher<sup>4</sup>, J Crown<sup>6</sup>, AR Fersht<sup>2</sup>, MJ Duffy<sup>1,7</sup>**  
<sup>1</sup>School of Medicine, University College Dublin, Dublin, <sup>2</sup>Laboratory of Molecular Biology, Medical Research Council, Cambridge, <sup>3</sup>Population Health Sciences, Royal College of Surgeons Ireland, Dublin, <sup>4</sup>UCD School of Biomolecular and Biomedical Science, University College Dublin, Dublin, <sup>5</sup>Department of Molecular & Cellular Therapeutics, Royal College of Surgeons Ireland, Dublin, <sup>6</sup>Department of Medical Oncology, St Vincent's University Hospital, Dublin, <sup>7</sup>Clinical Research Centre, St Vincent's University Hospital, Dublin

16.15-16.45 **XRCC6BP1: A KEY DNA REPAIR GENE IN CISPLATIN RESISTANT NON-SMALL CELL LUNG CANCER?**

**Martin P Barr**<sup>1</sup>, S Singh<sup>1</sup>, R Farrell<sup>1</sup>, E Foley<sup>1</sup>, Y He<sup>1</sup>, L Brady<sup>2</sup>, V Young<sup>3</sup>, R Ryan<sup>3</sup>, S Nicholson<sup>2</sup>, N Leonard<sup>2</sup>, S Cuffe<sup>1,4</sup>, S Finn<sup>1,2</sup>

<sup>1</sup>Thoracic Oncology Research Group, St James's Hospital & Trinity College Dublin, Dublin 8

<sup>2</sup>Histopathology Department, St James's Hospital & Trinity College Dublin, Dublin 8

<sup>3</sup>Cardiothoracic Surgery, St James's Hospital, Dublin 8

<sup>4</sup>Medical Oncology Department, St James's Hospital, Dublin 8

17.00-18.00: ***SPECIAL IACR CANCER RESEARCHER MEDAL PRESENTATION***

***Professor Patrick G. Johnston – IACR Award for Outstanding Contribution to Cancer Medicine & Research***

**Chair: Professor Amanda McCann**

**2018 - Remembering Professor Patrick G Johnston**

18.00 **CLOSE OF MEETING**

19.00 **GALA DINNER and Awards Presentations**  
***Followed by Traditional 'Céili' Night***

**Venue: Crowne Plaza Hotel**